EXTREME HYPERKALAEMIA CAUSED BY CONCOMITANT USE OF A NSAID AND AN ACE INHIBITOR IN AN ELDERLY PATIENT

被引:1
|
作者
Rogulj, Dinko [1 ]
Hauptfeld, Marko [2 ]
Iskra, Mojca Savnik [1 ]
Zorko, Vanda Kostevc [1 ]
Strasek, Milena [1 ]
机构
[1] Gen Hosp Brezice, Dept Internal Med, Brezice, Slovenia
[2] Gen Hosp Brezice, Dept Anesthesiol & Intens Care, Brezice, Slovenia
关键词
arterial hypertension; chronic diseases; diabetes mellitus; diclofenac; enalapril; side effects; DIALYSIS PATIENTS;
D O I
10.2478/10004-1254-61-2010-1997
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Extreme hyperkalaemia is a life-threatening electrolyte disorder. It is relatively common in patients with severe renal insufficiency. This report describes a case of extreme hyperkalaemia caused by drugs in an 82-year-old female patient without severe renal insufficiency, who was successfully treated without haemodialysis. The patient had been treated for arterial hypertension and type 2 diabetes mellitus for 30 years. Over the last years she had been receiving enalapril and metformin. Three weeks before the admission to the hospital, she was receiving a non-steroidal anti-inflammatory drug (NSAID) because of the back pain. She was admitted to hospital due to a collapse and weakness in the limbs. Laboratory tests showed extreme hyperkalaemia, high blood sugar, metabolic acidosis, elevated serum creatinine and blood urea nitrogen (BUN), and a slightly elevated serum sodium. On ECG, we noticed typical signs of hyperkalaemia. The patient was treated with a slow intravenous bolus of calcium gluconate and intravenous infusion of sodium chloride with insulin, glucose with insulin and sodium bicarbonte. After the treatment, all laboratory findings normalised together and the patient felt better. This case shows that physicians should be very careful when prescribing NSAIDs to elderly patients treated with drugs that affect renal function.
引用
收藏
页码:241 / 245
页数:5
相关论文
共 35 条
  • [31] Concomitant use of angiotensin converting enzyme inhibitor ACEI and angiotensin receptor blocker ARB in medication therapy of a co-morbid patient in a tertiary health care facility
    Khan, Aisha
    Farooq, Iqra
    Mairaj, Meena
    Abbas, Atta
    MEDICAL SCIENCE, 2014, 8-9 (28-35) : 67 - 70
  • [32] NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID), COX 2 INHIBITOR (COX 2) AND GASTRO-PROTECTIVE AGENT (GPA) USE IN A RHEUMATOLOGY OUT-PATIENT (OP) POPULATION
    Ledingham, J. M.
    Wood, A.
    McCrae, F. C.
    Hull, R. G.
    Thomas, A. L.
    Shaban, R. M.
    Mackay, K. R.
    Dennison, E.
    RHEUMATOLOGY, 2003, 42 : 102 - 103
  • [33] Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium-Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes-A Patient-Level Pooled Analysis
    Giorgino, Francesco
    Guja, Cristian
    Davies, Melanie J.
    Aydin, Hasan
    Lauand, Felipe
    Souhami, Elisabeth
    Melas-Melt, Lydie
    Aroda, Vanita R.
    Rosenstock, Julio
    DIABETES, 2023, 72
  • [34] Trends and Per-Patient Expenditures Associated With Proton Pump Inhibitor Use Among the Elderly in the United States: A 10-Year Analysis of the Medical Expenditure Panel Survey
    Alayo, Quazim A.
    Akanbi, Olalekan
    Nnanna, Onyema
    Adejumo, Adeyinka C.
    Okafor, Philip N.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S210 - S210
  • [35] A Study on the Glucose Breath Test Positivity Rate and Occurrence of Small Intestine Bacterial Overgrowth-Related Symptoms Caused by Long-Term Use of Proton Pump Inhibitor (PPI) Versus Potassium-Competitive Acid Blocker (P-CAB) in Elderly Patients SIBO Between PPI and P-CAB
    Lim, Na Rae
    Lim, Saenal
    Chung, Woo Chul
    ADVANCES IN PHARMACOLOGICAL AND PHARMACEUTICAL SCIENCES, 2024, 2024